Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare
Conference

CARMIEL, Israel, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the
Company's President and Chief Executive Officer, will present at the 32nd
Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at
12:00 PM, Pacific Time. The conference will be held at the Westin St. Francis
Union Square Hotel in San Francisco on January 13-16, 2014. A live webcast of
the presentation will be available at www.protalix.com on the event calendar
page. A replay will be archived and available after the conclusion of the
presentation for 90 days.

About Protalix

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell-based expression system, ProCellEx®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by theU.S. Food and Drug Administration (FDA) inMay 2012,
byIsrael'sMinistry of HealthinSeptember 2012, by theBrazilian National
Health Surveillance Agency(ANVISA) inMarch 2013, by theMexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) inApril 2013,
and by the regulatory authorities of other countries.Marketing applications
for taliglucerase alfa have been filed in additional territories as well.
Protalix has partnered withPfizer Inc.for the worldwide development and
commercialization of taliglucerase alfa, excludingIsraelandBrazil, where
Protalix retains full rights. Protalix's development pipeline also includes
the following product candidates: PRX-102, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry disease;
PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and
encapsulated within carrot cells, also for the treatment of Gaucher disease;
pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the
treatment of certain immune and inflammatory diseases, such as rheumatoid
arthritis, Chrohn's disease, colitis, psoriasis and other autoimmune and
inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; PRX-107
for the treatment of emphysema due to hereditary alpha1-antitrypsin
deficiency; and others.

CONTACT: Investor Contact
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com
        
         Media Contact
         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.